HBVtech

HBVtech is a private, preclinical-stage biotech company founded in 2016 and headquartered in Rockville, MD. The company's core asset is a proprietary gene therapy platform aimed at delivering lasting cures for chronic infections via a single injection, with its lead candidate targeting chronic hepatitis B. Operating as a pre-revenue therapeutics developer, HBVtech is positioned in a high-need market with significant unmet medical need, though it faces the technical and financial risks inherent to early-stage gene therapy development. Its success hinges on advancing its platform from preclinical research into clinical trials.

Proprietary gene therapy platform designed to deliver a lasting cure for chronic infections via a single injection. Platform is applicable to multiple chronic infections not adequately addressed by chronic therapies.

The pursuit of an HBV functional cure is a competitive space involving large pharma (e.g., Gilead, Janssen), biotech (e.g., Arbutus, Dicerna/Vir), and other gene therapy/editing approaches. Competitors are advancing multiple mechanisms including RNA interference, antisense oligonucleotides, capsid assembly modulators, and therapeutic vaccines. HBVtech's single-injection gene therapy approach must differentiate on durability, safety, and efficacy.